ADAG
NASD Adagene, Inc. Sponsored ADR$2.85 ↑ +0.00 (+0.00%) Trading Up from the previous close of $2.85, $0.15 below the day’s high of $3.00
- YTD change
- +50.79%
- vs 20-day SMA
- -11.89%
- vs 200-day SMA
- -14.72%
Price ranges
Price & Performance
-1.47 (-34.03%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 91.0% away from all-time highs of $31.83
- ADAG is up 51% since the beginning of the year
- ADAG is up 47% over the past 12 months
- ADAG is down 23% over the past 1 month
- 3% of all ADAG investors are betting against ADAG
ADAG reads poor: price sits below both the 20- and 200-day averages, the 12-month move is +43.2%.
- Previous minute
- +$0.00
- Last hour
- -$0.05
- Last 5 days
- -4.36%
- vs 8-day SMA
- -7.51%
No alerts for ADAG in the last day.
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Adagene, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of novel antibody-based cancer immunotherapies. Its dynamic precision library platform is composed of the following proprietary technologies: NEObody, SAFEbody, and POWERbody. The company was founded by Ge Li and Pei Zhi Luo on February 25, 2011 and is headquartered in Suzhou, China.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.